

Antipsychotic Drugs: Technologies and Global Markets

<https://marketpublishers.com/r/A19590A7BEFEN.html>

Date: September 2018

Pages: 174

Price: US\$ 1,375.00 (Single User License)

ID: A19590A7BEFEN

Abstracts

REPORT SCOPE:

This report provides a detailed description of the market for antipsychotic drugs. The report highlights the current and future market potential of antipsychotic drugs and provides a detailed analysis of the competitive environment, regulatory scenario, technological advancements, patent analysis, pipeline analysis, drivers, restraints, opportunities and trends in the market. The report also covers market projections through 2023, as well as market shares for key market players. The report segments the market for antipsychotic drugs based on mechanism of action, disease indication and geography. Based on mechanism of action, the market is segmented into D2 antagonists, D2/5HT2A antagonists and D2 partial agonists. The market size includes both branded and generic drugs. Based on disease indication, the market is segmented into schizophrenia, bipolar disorder, major depressive disorder (MDD), and other diseases including anxiety, autism and dementia. By geography, the market has been segmented into the North America, Europe, Asia-Pacific, South America, and Middle East and Africa regions. The North America region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., France, Italy, Spain and the rest of Europe. Asia-Pacific includes China, India, Japan and the rest of Asia-Pacific. For market estimates, data has been provided for 2017 as the base year, with forecasts for 2018 through 2023.

REPORT INCLUDES:

22 data tables and 36 additional tables

An overview of the global market for antipsychotic drugs

Analyses of global market trends, with data from 2017, estimates for 2018 and projections of CAGRs through 2023

Country specific data and analysis for United States, Canada, Mexico, UK, France, Germany, Italy, Spain, China, India and Japan

Definition, history and types of antipsychotic drugs

An understanding on receptor target of antipsychotic drugs, including dopamine, serotonin, glutamate, tachykinin and glucocorticoid

Coverage of various psychotic diseases and their indication including schizophrenia, bipolar disorder, major depressive disorder (MDD), anxiety, autism and dementia

Comprehensive company profiles of key players in the market, including Alexza Pharmaceuticals, Dr. Reddy's Laboratories, Ltd., Eli Lilly and Co., Johnson & Johnson, Teva Pharmaceutical Industries, Ltd., and Zydus Pharmaceuticals (USA), Inc.

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

Highlights

CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND

Overview: Antipsychotic Drugs
History of Antipsychotic Drugs
Types of Antipsychotic Drugs
Typical Antipsychotic Drugs
Atypical Antipsychotic Drugs
Receptor Target of Antipsychotic Drugs
Dopamine
Serotonin
Glutamate
Tachykinin
Glucocorticoid
Technology Overview
Formulations
Combination Therapies

CHAPTER 4 MARKET DYNAMICS

Market Drivers
Rising Incidence of Mental Disorders (Schizophrenia and Bipolar Disorder)

Government and NGO Initiatives in Creating Awareness Regarding Mental Illness
Growing Geriatric Population with Mental Disorders
Increasing Prevalence of Depression and Anxiety
Market Restraints
Patent Expirations of Branded Drugs and Emergence of Generics
Adverse Side Effects Associated with Antipsychotic Drugs
Market Opportunities
Unmet Needs in Low-and Middle-Income Countries
Widening Disease Indication Areas for Antipsychotic Drugs
Loss of Patent Exclusivity: Lucrative Opportunity for Generic Manufacturers

CHAPTER 5 MARKET BREAKDOWN BY MECHANISM OF ACTION

Global Antipsychotic Drug Market
D2 Antagonists
Market Size and Forecast
Market Analysis
D2/5HT2A Antagonists
Market Size and Forecast
Market Analysis
D2 Partial Agonists
Market Size and Forecast
Market Analysis

CHAPTER 6 MARKET BREAKDOWN BY DISEASE INDICATION

Global Antipsychotic Drugs Market, by Disease Indication
Schizophrenia
Overview
Market Size and Forecast
Market Analysis
Bipolar Disorder
Overview
Market Size and Forecast
Market Analysis
Major Depressive Disorder
Overview
Market Size and Forecast
Market Analysis

Other Disease Indications
Overview
Market Size and Forecast
Market Analysis

CHAPTER 7 MARKET BREAKDOWN BY REGION

Global Market for Antipsychotic Drugs, by Region
North America
United States
Canada
Mexico
Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Rest of Asia-Pacific
South America
Prevalence of Mental Illness in South America
Middle East and Africa
Prevalence of Mental Illness in the Middle East and Africa

CHAPTER 8 REGULATORY SCENARIO

Regulations in the U.S.
New Drug Approval
Controlled Substances Act
The FDA Modernization Act of 1997
Fast Track Status
Special Protocol Assessments
New Surveillance and Safety Requirements
Medicare

Regulations in Europe
Pricing and Reimbursement
Regulations in Japan

CHAPTER 9 PATENT ANALYSIS

Patent Lengths and Market Exclusivity

CHAPTER 10 PIPELINE ANALYSIS

Overview of the Drug Development Process
Pipeline Analysis of Antipsychotic Drugs
Drugs in Phase I Clinical Trials
Drugs in Phase II Clinical Trials
Drugs in Phase II Clinical Trials
Late Stage Clinical Trials for Novel Drug Candidates

CHAPTER 11 COMPETITIVE LANDSCAPE

Global Company Share Analysis
Impact of Generic Antipsychotic Drugs on the Market

CHAPTER 12 COMPANY PROFILES

ACADIA PHARMACEUTICALS, INC.
Company Overview
Financials
Product Portfolio
Development and Strategies
ALEMBIC PHARMACEUTICALS, LTD.
Company Overview
Financials
Product Portfolio
Development and Strategies
ALEXZA PHARMACEUTICALS
Company Overview
Product Portfolio
Development and Strategies
ALKERMES PLC

Company Overview

Financials

Regional Revenue

Product Portfolio

Development and Strategies

ALLERGAN PLC

Company Overview

Financials

Product Portfolio

Development and Strategies

APOTEX, INC.

Company Overview

Product Portfolio

Development and Strategies

ASTRAZENECA PLC

Company Overview

Financials

AstraZeneca PLC Business Segment Revenue

AstraZeneca PLC Revenue by Region Segment

Product Portfolio

Development and Strategies

AUROBINDO PHARMA

Company Overview

Financials

Product Portfolio

Development and Strategies

DR. REDDY'S LABORATORIES LTD.

Company Overview

Financials

Product Portfolio

Development and Strategies

ELI LILLY AND CO.

Company Overview

Financials

Product Portfolio

Development and Strategies

GEDEON RICHTER PLC

Company Overview

Financials

Gedeon Richter PLC Business Segment Revenue

Gedeon Richter PLC Revenue by Region

Product Portfolio

Development and Strategies

JOHNSON & JOHNSON

Company Overview

Financials

Product Portfolio

Development and Strategies

LANNETT CO., INC.

Company Overview

Financials

Product Portfolio

Development and Strategies

H. LUNDBECK A/S

Company Overview

Financials

H. Lundbeck A/S Region Segment Revenue

Product Portfolio

Development and Strategies

LUPIN, LTD.

Company Overview

Financials

Product Portfolio

Development and Strategies

MAYNE PHARMA, INC.

Company Overview

Financials

Product Portfolio

Development and Strategies

MYLAN NV

Company Overview

Financials

Product Portfolio

Development and Strategies

OTSUKA HOLDINGS CO., LTD.

Company Overview

Financials

Otsuka Holdings Co. Ltd. Revenue by Business Segment

Otsuka Holdings Co., Ltd. Revenue by Region

Product Portfolio

Development and Strategies

SUMITOMO DAINIPPON PHARMA CO., LTD.

Company Overview

Financials

Sumitomo Dainippon Pharma Co. Ltd. Revenue by Region

Product Portfolio

Development and Strategies

SUN PHARMACEUTICAL INDUSTRIES LIMITED (SUN PHARMA)

Company Overview

Financials

Product Portfolio

Development and Strategies

TEVA PHARMACEUTICAL INDUSTRIES, LTD.

Company Overview

Financials

Product Portfolio

Development and Strategies

TORRENT PHARMACEUTICALS, LTD.

Company Overview

Financials

Product Portfolio

Development and Strategies

VANDA PHARMACEUTICALS, INC

Company Overview

Financials

Product Portfolio

Development and Strategies

WOCKHARDT

Company Overview

Financials

Product Portfolio

Development and Strategies

ZYDUS PHARMACEUTICALS (USA), INC.

Company Overview

Financials

Product Portfolio

Development and Strategies

CHAPTER 13 LIST OF ABBREVIATIONS

List Of Tables

LIST OF TABLES

Summary Table: Global Market for Antipsychotic Drugs, by Mechanism of Action, Through 2023

Table 1: Currently Approved Atypical Antipsychotics in the Market

Table 2: Administration Profile of Long-acting Atypical Antipsychotic Drugs

Table 3: Number of Bipolar Disorder Patients, by Country, 2018

Table 4: Patent Expiration Dates for Antipsychotic Drugs

Table 5: Number of Warnings About Antipsychotic Drugs

Table 6: Abilify Revenue, 2014-2017

Table 7: Indicative List of Available Generic Versions of Abilify

Table 8: Global Market for Antipsychotic Drugs, by Mechanism of Action, Through 2023

Table 9: D2 Antagonist Drugs: Market Presence

Table 10: Adverse Effects Profile of D2 Antagonist/Typical Antipsychotic Drugs

Table 11: Global Market for Antipsychotic Drugs, by Disease Indication, Through 2023

Table 12: Global Market for Antipsychotic Drugs, by Region, Through 2023

Table 13: North American Market for Antipsychotic Drugs, by Country, Through 2023

Table 14: Prevalence of Serious Mental Illness Among Adults, by State, U.S., 2017

Table 15: Prevalence of Mental Illness, by Disease Indication, U.S., 2017

Table 16: Prevalence of Mental Illness, by Disease Indication, Canada

Table 17: European Market for Antipsychotic Drugs, by Country, Through 2023

Table 18: Prevalence of Mental Illness, by Disease Indication, Germany, 2016

Table 19: Prevalence of Mental Illness, by Disease Indication, U.K., 2017

Table 20: Prevalence of Mental Illness, by Disease Indication, France, 2014

Table 21: Prevalence of Mental Illness, by Disease Indication, Italy, 2017

Table 22: Prevalence of Mental Illness, by Disease Indication, Spain, 2016

Table 23: Asia-Pacific Market for Antipsychotic Drugs, by Country, Through 2023

Table 24: Prevalence of Mental Illness, by Disease Indication, Japan, 2017

Table 25: Prevalence of Mental Illness, by Disease Indication, China, 2017

Table 26: Prevalence of Mental Illness, by Disease Indication, India, 2016

Table 27: Patent Expiration of Antipsychotic Drugs

Table 28: Exclusivity Expiration of Antipsychotic Drugs

Table 29: Phase I Pipeline of Antipsychotic Drugs

Table 30: Phase II Pipeline of Antipsychotic Drugs

Table 31: Phase III Pipeline of Antipsychotic Drugs

Table 32: Acadia Pharmaceuticals: Antipsychotic Drugs Product Portfolio

Table 33: Alembic Pharmaceuticals, Ltd.: Antipsychotic Drugs Product Portfolio

Table 34: Alexza Pharmaceuticals: Antipsychotic Drugs Product Portfolio
Table 35: Alkermes PLC: Antipsychotic Drugs Product Portfolio
Table 36: Allergan PLC: Antipsychotic Drugs Product Portfolio
Table 37: Apotex, Inc.: Antipsychotic Drugs Product Portfolio
Table 38: AstraZeneca PLC: Antipsychotic Drugs Product Portfolio
Table 39: Aurobindo Pharma: Antipsychotic Drugs Product Portfolio
Table 40: Dr. Reddy's Laboratories, Ltd.: Antipsychotic Drugs Product Portfolio
Table 41: Eli Lilly and Co.: Products
Table 42: Gedeon Richter PLC: Antipsychotic Drugs Product Portfolio
Table 43: Johnson & Johnson: Antipsychotic Drugs Product Portfolio
Table 44: Lannett Co.: Antipsychotic Drugs Product Portfolio
Table 45: H. Lundbeck A/S: Antipsychotic Drugs Product Portfolio
Table 46: Lupin, Ltd.: Antipsychotic Drugs Product Portfolio
Table 47: Mayne Pharma, Inc.: Antipsychotic Drugs Product Portfolio
Table 48: Mylan NV: Antipsychotic Drugs Product Portfolio
Table 49: Otsuka Holdings Co., Ltd.: Antipsychotic Drugs Product Portfolio
Table 50: Sumitomo Dainippon Pharma Co., Ltd.: Antipsychotic Drugs Product Portfolio
Table 51: Sun Pharmaceuticals Industries, Ltd.: Antipsychotic Drugs Product Portfolio
Table 52: Teva Pharmaceutical Industries, Ltd.: Antipsychotic Drugs Product Portfolio
Table 53: Torrent Pharmaceuticals, Ltd.: Antipsychotic Drugs Product Portfolio
Table 54: Vanda Pharmaceuticals, Inc.: Antipsychotic Drugs Product Portfolio
Table 55: Wockhardt: Antipsychotic Drugs Product Portfolio
Table 56: Zydus Pharmaceuticals (USA), Inc.: Antipsychotic Drugs Product Portfolio
Table 57: Abbreviations Used in Antipsychotic Drugs: Technologies and Global Markets

List Of Figures

LIST OF FIGURES

Summary Figure: Global Market Share for Antipsychotic Drugs, by Mechanism of Action, 2017

Figure 1: Number of Depressive Disorder Patients, by Region, 2015

Figure 2: Number of Patients with Anxiety Disorders, by Region, 2015

Figure 3: Global Market Share for Antipsychotic Drugs, by Mechanism of Action, 2017

Figure 4: Global Market for Antipsychotic Drugs in D2 Antagonist, 2017-2023

Figure 5: Global Market for Antipsychotic Drugs in D2/5HT2A Antagonist, 2017-2023

Figure 6: Eli Lilly and Company: Sales Revenue for Zyprexa Franchise, 2014-2017

Figure 7: Johnson & Johnson: Sales Revenue for Invega, 2012-2015

Figure 8: Johnson & Johnson Sales Revenue for Invega Sustenna Franchise, 2014-2017

Figure 9: Johnson & Johnson: Sales Revenue for Risperdal Consta, 2014-2017

Figure 10: AstraZeneca: Sales Revenue for Seroquel IR, 2014-2017

Figure 11: AstraZeneca: Sales Revenue for Seroquel XR, 2014-2017

Figure 12: Sumitomo Dainippon Pharma Co. Ltd.: Sales Revenue for Latuda, 2015-2017

Figure 13: Sumitomo Dainippon Pharma Co. Ltd.: Sales Revenue for Lonasen, 2015-2017

Figure 14: Vanda Pharmaceuticals: Sales Revenue for Fanapt Franchise, 2015-2017

Figure 15: Allergan: Sales Revenue for Saphris, 2015-2017

Figure 16: Global Market for Antipsychotic Drugs in D2 Partial Agonist, 2017-2023

Figure 17: Otsuka Holdings Co. Ltd.: Sales Revenue for Abilify, 2014-2017

Figure 18: Otsuka Holdings Co. Ltd.: Sales Revenue for Abilify Maintena, 2015-2017

Figure 19: Otsuka Holdings Co. Ltd.: Sales Revenue for Rexulti, 2015-2017

Figure 20: Alkermes: Sales Revenue for Aristada, 2015-2017

Figure 21: Allergan: Sales Revenue for Vraylar, 2016 and 2017

Figure 22: Global Market Share for Antipsychotic Drugs, by Disease Indication, 2017

Figure 23: Global Market for Antipsychotic Drugs in Schizophrenia, 2017-2023

Figure 24: Global Market for Antipsychotic Drugs in Bipolar Disorder, 2017-2023

Figure 25: Global Market for Antipsychotic Drugs in Major Depressive Disorder (MDD), 2017-2023

Figure 26: Global Market for Antipsychotic Drugs in Other Disease Indications, 2017-2023

Figure 27: Global Market Share for Antipsychotic Drugs, by Region, 2017

Figure 28: North American Market Share for Antipsychotic Drugs, by Country, 2017

- Figure 29: U.S. Market for Antipsychotic Drugs, 2017-2023
- Figure 30: Canadian Market for Antipsychotic Drugs, 2017-2023
- Figure 31: Mexican Market for Antipsychotic Drugs, 2017-2023
- Figure 32: European Market Share for Antipsychotic Drugs, by Country, 2017
- Figure 33: German Market for Antipsychotic Drugs, 2017-2023
- Figure 34: U.K. Market for Antipsychotic Drugs, 2017-2023
- Figure 35: French Market for Antipsychotic Drugs, 2017-2023
- Figure 36: Italian Market for Antipsychotic Drugs, 2017-2023
- Figure 37: Spanish Market for Antipsychotic Drugs, 2017-2023
- Figure 38: Rest of Europe Market for Antipsychotic Drugs, 2017-2023
- Figure 39: Asia-Pacific Market Share for Antipsychotic Drugs, by Country, 2017
- Figure 40: Japanese Market for Antipsychotic Drugs, 2017-2023
- Figure 41: Chinese Market for Antipsychotic Drugs, 2017-2023
- Figure 42: Indian Market for Antipsychotic Drugs, 2017-2023
- Figure 43: Rest of Asia-Pacific Market for Antipsychotic Drugs, 2017-2023
- Figure 44: South American Market for Antipsychotic Drugs, 2017-2023
- Figure 45: Middle East and African Market for Antipsychotic Drugs, 2017-2023
- Figure 46: Global Market Share for Antipsychotic Drugs, by Manufacturer, 2017
- Figure 47: Acadia Pharmaceuticals: Financial Performance, 2016 and 2017
- Figure 48: Alembic Pharmaceuticals, Ltd.: Financial Performance, 2015-2017
- Figure 49: Alkermes PLC: Annual Revenue, 2014-2017
- Figure 50: Alkermes PLC: Revenue Share, by Region, 2017
- Figure 51: Allergan PLC: Annual Revenue, 2013-2017
- Figure 52: Allergan PLC: Revenue Share, by Business Unit, 2017
- Figure 53: AstraZeneca PLC: Financial Performance, 2013-2017
- Figure 54: AstraZeneca PLC: Revenue Share, by Business Unit, 2017
- Figure 55: AstraZeneca PLC: Revenue Share, by Region, 2017
- Figure 56: Aurobindo Pharma: Financial Performance, 2015-2017
- Figure 57: Dr. Reddy's Laboratories, Ltd.: Financial Performance, 2015-2017
- Figure 58: Eli Lilly and Co.: Revenue, 2013-2017
- Figure 59: Eli Lilly and Co.: Revenue Share, by Region, 2017
- Figure 60: Eli Lilly and Co.: Revenue Share, by Business Unit, 2017
- Figure 61: Gedeon Richter PLC: Financial Performance, 2014-2017
- Figure 62: Gedeon Richter PLC: Revenue Share, by Business Unit, 2017
- Figure 63: Gedeon Richter PLC: Revenue Share, by Region, 2017
- Figure 64: Johnson & Johnson: Revenue, 2013-2017
- Figure 65: Johnson & Johnson: Revenue Share, by Region, 2017
- Figure 66: Johnson & Johnson: Revenue Share, by Business Unit, 2017
- Figure 67: Lannett Co.: Financial Performance, 2015-2017

- Figure 68: H. Lundbeck A/S: Financial Performance, 2013-2017
- Figure 69: H. Lundbeck A/S: Revenue Share, by Region, 2017
- Figure 70: Lupin, Ltd.: Financial Performance, 2015-2017
- Figure 71: Lupin, Ltd.: Revenue Shares, by Business Segment, 2017
- Figure 72: Mayne Pharma, Inc.: Financial Performance, 2015-2017
- Figure 73: Mylan NV: Financial Performance, 2014-2017
- Figure 74: Mylan NV: Revenue Share, by Region, 2017
- Figure 75: Otsuka Holdings Co., Ltd.: Financial Performance, 2013-2017
- Figure 76: Otsuka Holdings Co., Ltd.: Revenue Share, by Business Unit, 2017
- Figure 77: Otsuka Holdings Co., Ltd.: Revenue Share, by Region, 2017
- Figure 78: Sumitomo Dainippon Pharma Co., Ltd.: Financial Performance, 2013-2017
- Figure 79: Sumitomo Dainippon Pharma Co. Ltd.: Revenue Shares, by Region, 2017
- Figure 80: Sun Pharmaceuticals Industries, Ltd.: Financial Performance, 2015-2017
- Figure 81: Teva Pharmaceutical Industries, Ltd.: Financial Performance, 2015-2017
- Figure 82: Teva Pharmaceutical Industries, Ltd.: Revenue Share, by Region, 2017
- Figure 83: Teva Pharmaceutical Industries, Ltd.: Revenue Share, by Business Segment, 2016
- Figure 84: Torrent Pharmaceuticals, Ltd.: Financial Performance, 2015-2017
- Figure 85: Vanda Pharmaceuticals, Inc.: Annual Revenue, 2013-2017
- Figure 86: Wockhardt: Financial Performance, 2015-2017
- Figure 87: Wockhardt: Revenue Share, by Region, 2017
- Figure 88: Zydus Pharmaceuticals (USA), Inc.: Financial Performance, 2015-2017

I would like to order

Product name: Antipsychotic Drugs: Technologies and Global Markets

Product link: <https://marketpublishers.com/r/A19590A7BEFEN.html>

Price: US\$ 1,375.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A19590A7BEFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970